Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next?

Gain Therapeutics, Inc. (NASDAQ:GANX)’s share price was up 10.4% during mid-day trading on Wednesday . The stock traded as high as $2.45 and last traded at $2.44. Approximately 255,189 shares changed hands during trading, an increase of 23% from the average daily volume of 207,210 shares. The stock had previously closed at $2.21.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, November 25th. Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Roth Mkm restated a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Stock Up 10.4 %

The business has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $1.78. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The firm has a market capitalization of $64.71 million, a price-to-earnings ratio of -2.22 and a beta of 0.14.

Institutional Trading of Gain Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sprott Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at $30,000. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics in the fourth quarter worth $35,000. Renaissance Technologies LLC raised its stake in shares of Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after acquiring an additional 72,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.